Repository logo
 
Publication

Antibodies Towards High-Density Lipoprotein Components in Patients with Psoriasis

2020Journal article Open access
Simple item page
dc.contributor.authorHu, LS
dc.contributor.authorZhang, XF
dc.contributor.authorWeiss, M
dc.contributor.authorPopescu, I
dc.contributor.authorPinto Marques, H
dc.contributor.authorDelgado Alves, L
dc.contributor.authorMaithel, S
dc.contributor.authorPulitano, C
dc.contributor.authorBauer, T
dc.contributor.authorShen, F
dc.contributor.authorPoultsides, G
dc.contributor.authorSoubrane, O
dc.contributor.authorMartel, G
dc.contributor.authorKoerkamp, B
dc.contributor.authorItaru, E
dc.contributor.authorLv, Y
dc.contributor.authorPawlik, T
dc.date.accessioned2024-05-15T15:35:18Z
dc.date.available2024-05-15T15:35:18Z
dc.date.issued2020
dc.description.abstractObjectives: To assess conditional survival (CS) according to recurrence status, as well as conditional disease-free survival (cDFS) among patients with intrahepatic cholangiocarcinoma (ICC). Methods: CS and cDFS were evaluated among ICC patients who underwent curative-intent resection for ICC by using a multi-institutional database. Five-year CS (CS5) at "x" years was calculated separately for patients who did and did not experience recurrence. The cDFS3 at "x" years was defined as the chance to be disease-free for an additional 3 years after not having experienced a recurrence for "x" years postoperatively. Results: Among 1221 patients, median OS was 36.8 months. While estimated actuarial OS decreased over time, CS5 increased as patients survived over longer periods of time and reached 93.9% at 4 years among 139 patients who did not experience a recurrence. Among the 725 (59.4%) patients who did experience a tumor recurrence, CS5 decreased to 17.7% the first postoperative year; however, CS5 subsequently increased to 79.7% for 81 patients who had survived 4 years after surgery. While actuarial DFS decreased from 54.6% at 1 year to 28.2% at 5 years, estimated cDFS3 following liver resection increased over time. Of note, patients with known risk factors for recurrence had even more marked improvements in cDFS3 over subsequent years versus patients without risk factors for recurrence. Conclusion: CS and cDFS changed over time according to the presence of disease-specific risk factors, as well as the presence of recurrence.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Gastrointest Surg . 2020 Dec;24(12):2756-2765.pt_PT
dc.identifier.doi10.1007/s11605-019-04472-xpt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4902
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringerpt_PT
dc.subjectHCC CIRpt_PT
dc.subjectHumanspt_PT
dc.subjectBile Duct Neoplasms* / surgerypt_PT
dc.subjectCholangiocarcinoma* / surgerypt_PT
dc.subjectDisease-Free Survivalpt_PT
dc.subjectFollow-Up Studiespt_PT
dc.subjectHepatectomypt_PT
dc.subjectNeoplasm Recurrence, Local / epidemiologypt_PT
dc.subjectNeoplasm Recurrence, Local / surgerypt_PT
dc.subjectPrognosispt_PT
dc.titleAntibodies Towards High-Density Lipoprotein Components in Patients with Psoriasispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage2765pt_PT
oaire.citation.issue12pt_PT
oaire.citation.startPage2756pt_PT
oaire.citation.titleJournal of Gastrointestinal Surgerypt_PT
oaire.citation.volume24pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
J Gastrointest Surg 2020 2756.pdf
Size:
1.69 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

CIR - Artigos